The $70M upfront provides immediate cash runway and validates navenibart's commercial potential. Monitor Phase 3 data readouts and milestone triggers (regulatory filings) for further upside. The partnership reduces European commercial risk.
BCRX drugs
BCRX drug pipeline →How the stock moved after the report
BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · May 4 $9.20entry
- T+1 · 7mo ago −1.85%α −2.64% · $9.03
- T+5 · 6mo ago −6.74%α −9.68% · $8.58
- T+20 · 6mo ago −6.85%α −12.49% · $8.57
- T+60 · 4mo ago +3.59%α +1.73% · $9.53
Price Chart
How similar events traded
Executive Summary
BioCryst entered a European licensing agreement for navenibart (HAE) with Neopharmed Gentili, receiving $70M upfront and up to $275M in milestones plus tiered royalties (18-30%). The deal strengthens the balance sheet and provides non-dilutive capital while retaining significant upside. Phase 3 remains on track for US filing by end-2027.
Key Facts
- $70 million upfront payment
- Up to $275 million in future regulatory and sales milestone payments
- Tiered royalties on net sales ranging from 18% to 30%
- Neopharmed Gentili gains exclusive European commercialization rights
- Navenibart Phase 3 program on track for US regulatory filing by end of 2027
- Builds on prior 2025 agreement for ORLADEYO European business sale
Financial Impact
Upfront $70M cash infusion, potential total deal value up to $345M including milestones, plus ongoing royalties (18-30%)
Risk Factors
- Clinical trial failure or regulatory delays for navenibart
- Milestone and royalty payments depend on approval and commercial success
- Partner execution risk in European market
- Potential dilution if future capital needs exceed expectations
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001171843-26-002960 |
| Exhibit: exh_991.htm | 0001171843-26-002960 |
| Document: 0001171843-26-002960-index-headers.html | 0001171843-26-002960 |
| Document: 0001171843-26-002960-index.html | 0001171843-26-002960 |
| Document: 0001171843-26-002960.txt | 0001171843-26-002960 |
Track record
20 reports on BCRX
The track record builds as more bullish or bearish reports settle.
Filters
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $7.71 Now $7.45 −3.35% settles Feb 16
- Nov 13, 20263d ago Press Release Neutral 3/10 Entry $7.61 Now $7.45 −2.10% settles Feb 11
- Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $7.53 Now $7.45 −1.06% settles Feb 8
- Nov 4, 202612d ago 8-K Bullish 6/10 No price data
- Nov 4, 202612d ago Press Release Bullish 6/10 Entry $8.24 Now $7.45 −9.59% settles Feb 2
- Nov 2, 202614d ago Institutional Cluster Neutral 3/10 Entry $8.57 Now $7.45 −13.07% settles Feb 1
- Oct 27, 202620d ago Institutional Cluster Mixed 3/10 Entry $8.37 Now $7.45 −10.99% settles Jan 26
- Oct 21, 202626d ago Press Release Neutral 1/10 Entry $7.78 Now $7.45 −4.24% settles Jan 20
- Aug 5, 202614w ago 8-K Bullish 7/10 Entry $9.07 to $8.46 Now $7.45 −17.86% ▼ −6.73% −6.92% vs SPY
- Jun 29, 202620w ago 8-K Neutral 5/10 Entry $9.55 to $8.78 Now $7.45 −21.99% ▼ −8.06% −12.45% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers